Cost-effectiveness analysis of tranexamic acid for the treatment of traumatic brain injury, based on the results of the CRASH-3 randomised trial: a decision modelling approach

IntroductionAn estimated 69 million traumatic brain injuries (TBI) occur each year worldwide, with most in low-income and middle-income countries. The CRASH-3 randomised trial found that intravenous administration of tranexamic acid within 3 hours of injury reduces head injury deaths in patients sus...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMJ global health 2020-09, Vol.5 (9), p.e002716
Hauptverfasser:	Williams, Jack, Roberts, Ian, Shakur-Still, Haleema, Lecky, Fiona E, Chaudhri, Rizwana, Miners, Alec
Format:	Artikel
Sprache:	eng
Schlagworte:	Acids Antifibrinolytic agents Brain Injuries, Traumatic - drug therapy Cost analysis Cost-Benefit Analysis Decision Support Techniques Disability Drug dosages Global health Head injuries health economics High income Humans Income injury Intravenous administration Original Research Pakistan Public health Quality of Life Sensitivity analysis Tranexamic Acid - therapeutic use Traumatic brain injury
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!